During his tenure in Academia Sinica, Dr. Chang’s team invented two new lead biologics, an anti-CemX antibody (FB825) and a new form of the anti-IgE antibody (UB221). These two antibodies have been licensed to Fountain Biopharma, Inc. and United BioPharma, Inc., respectively, in Taiwan for clinical development.